Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular ...

Adults whose type 2 diabetes was treated with GLP-1 receptor agonists were more likely to develop cognitive impairment over 10 years than their counterparts not treated with GLP-1 agents, a propensity ...

A study has found that an emerging class of GLP-1 weight-loss drugs suppresses eating for pleasure, or hedonic feeding, in ...

GLP-1 medications can reduce your appetite, potentially leading to lower levels of certain vitamins or supplements. People with obesity or type 2 diabetes, which these medications are used to treat, ...

Mounting evidence of improved outcomes as add-on to psoriasis drugs in patients with obesi ...

Medicare has delayed a program for older Americans that would've required participating insurance companies to cover GLP-1 weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

April 24 (Reuters) - An outpatient endoscopic procedure used to treat type 2 diabetes can help prevent people from regaining weight after they discontinue taking GLP-1 drugs, interim results from a ...

The medication, typically used for weight loss or diabetes treatment, is showing promise curbing cravings for alcohol and ...

Use of GLP-1 receptor agonists continues to shift rapidly, with early April developments highlighting changes in pricing models, drug access, regulatory oversight and personalized care. Novo Nordisk ...

Amazon is rolling out a new GLP‑1 program aimed at simplifying access to popular weight-loss drugs, from doctor visits to prescription delivery. The company announced on April 21 that Amazon One ...

If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight loss journey on GLP-1 medications in a commercial. Like millions of others around the country, if you’ve ever ...